Investigating Hodgkin lymphoma in people living with HIV in South Africa
Official title: Hodgkin Lymphoma in PLWH in South Africa: TB, EBV, and Tumor Molecular Markers
Funded at Johns Hopkins University · NIH-10825552 · Data updated 2026-11-12
This study is looking at how Hodgkin lymphoma affects people living with HIV in South Africa, comparing their experiences with those who don’t have HIV, to better understand how factors like organ health and other infections might influence treatment and outcomes.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project start | April 1, 2020 |
| Project end | September 30, 2025 |
| Funding year | 2024 |
| Award (this year) | $848,142 |
| NIH project number | 5R01CA250069-05 |
| Project ID | NIH-10825552 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Hodgkin lymphoma who are also living with HIV in South Africa.
✕Less likely to help
Patients who do not have Hodgkin lymphoma or are not living with HIV may not receive any benefit from this research.
What this research studies
This research focuses on understanding the outcomes of Hodgkin lymphoma (HL) in individuals living with HIV in South Africa, where their prognosis is often worse compared to those without HIV. The study will observe both HIV-positive and HIV-negative patients to assess various factors such as performance status, organ function, clinical stage, and the presence of Epstein-Barr virus (EBV) in tumors. Additionally, it will explore the impact of tuberculosis (TB) co-infection on treatment responses and mortality rates. By utilizing minimally invasive autopsy techniques, the research aims to gather comprehensive data on causes of death and treatment efficacy.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies and outcomes for Hodgkin lymphoma patients living with HIV.
How similar studies have gone: Previous research has shown that understanding the interplay between HIV and cancer can lead to better treatment outcomes, indicating that this approach has potential for success.
Where this research is happening
-
Johns Hopkins University
Baltimore, United States Active
Researchers
- Principal investigator: Ambinder, Richard Frederick — Johns Hopkins University
- Study coordinator: Ambinder, Richard Frederick
Related research
Other NIH-funded projects on the same topics.
-
Understanding why Black and Hispanic Hodgkin lymphoma patients have worse survival
A patient-centered study to uncover social and care factors that contribute to lower survival among Black and Hispanic people with Hodgkin lymphoma across all ages.
-
Novel combination therapy for non-Hodgkin lymphoma in people and dogs
A new treatment combo using an oncolytic virus and other therapies is being tested to help people with hard-to-treat non-Hodgkin lymphoma, with studies also involving dogs to better understand responses.
-
Trajectories of Neurotoxicity in young Hodgkin lymphoma patients
Aging Hodgkin lymphoma patients who are adolescents or young adults may face long-lasting brain and nerve-related side effects from their cancer treatment, and this study aims to map how those problems develop over time.
-
Combination therapy approach for non-Hodgkin lymphoma (NHL)
A Mayo Clinic team is testing a new combination treatment for non-Hodgkin lymphoma to improve responses in patients and in dogs with similar disease.
-
Multi-antigen T cell therapy for relapsed NHL
A patient-derived T cell therapy called MT-601 targets six tumor-associated antigens to help treat relapsed non-Hodgkin lymphoma after other therapies may have failed.
-
Personalized de‑intensification of therapy for NLP Hodgkin lymphoma
A clinician-scientist at Stanford is developing a patient-centered program to tailor and reduce therapy for nodular lymphocyte-predominant Hodgkin lymphoma using tumor and blood samples.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.